{
  "schemaVersion" : 2,
  "registerId" : "F2018L01480",
  "instrumentNumber" : "97/2018",
  "citation" : "Statement of Principles concerning human T-cell lymphotropic virus type-1 infection (Balance of Probabilities) (No. 97 of 2018)",
  "conditionName" : "human T-cell lymphotropic virus type-1 infection",
  "effectiveFrom" : "2018-11-26",
  "standardOfProof" : "Balance of Probabilities",
  "icdCodes" : [ {
    "version" : "ICD-10-AM",
    "code" : "Z22.6"
  } ],
  "onsetFactors" : [ {
    "paragraph" : "9(1)",
    "text" : "being exposed to HTLV-1 before the clinical onset of human T-cell\r\nlymphotropic virus type-1 infection",
    "definedTerms" : [ {
      "term" : "being exposed to HTLV-1",
      "definition" : "means:\r\n(a) having percutaneous exposure (intravenous, intramuscular,\r\nsubcutaneous or intradermal) or permucosal exposure to a specified\r\nbody substance which is derived from a person infected with HTLV-1;\r\nor\r\n(b) having a tissue or organ transplant, where the tissue or organ is derived\r\nfrom a person infected with HTLV-1.\r\nNote: specified body substance is also defined in the Schedule 1 - Dictionary.\r\nhuman T-cell lymphotropic virus type-1 infectionâ€”see subsection 7(2)."
    } ]
  } ],
  "aggravationFactors" : [ {
    "paragraph" : "9(2)",
    "text" : "inability to obtain appropriate clinical management for human T-cell\r\nlymphotropic virus type-1 infection",
    "definedTerms" : [ ]
  } ]
}